Immune therapy and β-cell death in type 1 diabetes

Area of Science:

• Immunology
• Endocrinology
• Biochemistry

Background:

• Type 1 diabetes (T1D) involves immune-mediated destruction of insulin-producing beta-cells.
• Current methods cannot directly measure beta-cell death, hindering research into disease mechanisms and therapies.
• Distinguishing beta-cell death from dysfunction is challenging due to confounding factors like glucose levels.

Purpose of the Study:

• To develop and validate a novel assay for measuring beta-cell death.
• To assess beta-cell death rates in recent-onset and long-standing T1D patients.
• To evaluate the impact of teplizumab, an anti-CD3 monoclonal antibody, on beta-cell death and function in a clinical trial.

Main Methods:

• Developed a serum-based assay measuring relative levels of unmethylated INS DNA to detect beta-cell death.
• Studied three groups: recent-onset T1D patients, long-standing T1D patients, and non-diabetic control subjects.
• Analyzed data from a clinical trial involving T1D patients treated with teplizumab or placebo.

Main Results:

• Patients with recent-onset T1D exhibited higher rates of beta-cell death compared to non-diabetic controls.
• Patients with long-standing T1D showed lower levels of beta-cell death.
• Teplizumab treatment in recent-onset T1D patients significantly reduced beta-cell death rates and preserved beta-cell function (C-peptide response).

Conclusions:

• The novel assay effectively measures beta-cell death in T1D.
• Increased beta-cell death is characteristic of recent-onset T1D.
• Immune intervention with teplizumab is associated with decreased beta-cell death and improved beta-cell function in T1D.